Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease

Advances in Alzheimer's Disease

Volumn 3, Issue , 2012, Pages 329-347

  Teipel, Stefan J ^a,b   Sabri, Osama ^c   Grothe, Michel ^a   Barthel, Henryk ^c   Prvulovic, David ^d   Buerger, Katharina ^e   Bokde, Arun L W ^f,g   Ewers, Michael ^h,i   Hoffmann, Wolfgang ^b,j   Hampel, Harald ^d  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f TRINITY COLLEGE DUBLIN   (Ireland)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY MEDICINE GREIFSWALD   (Germany)

more..

Author keywords

Alzheimer's disease; amyloid; atrophy; biomarker; blood; cerebrospinal fluid; diagnosis; diffusion tensor imaging; hippocampus; mild cognitive impairment; neurodegeneration; neuroimaging; pathophysiology; positron emission tomography; prognosis; resting state functional magnetic resonance imaging; tau; therapy

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN ATROPHY; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; CEREBRAL CONNECTIVITY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; DIFFUSION TENSOR IMAGING; DISEASE CLASSIFICATION; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LUMBAR PUNCTURE; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; RISK FACTOR;

EID: 84877934503     PISSN: 22105727     EISSN: 22105735     Source Type: Book Series    
DOI: 10.3233/978-1-61499-154-0-329     Document Type: Article

References (156)

1. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, PhelpsCH(2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262
2. Seab JP, Jagust WJ,Wong ST, Roos MS, Reed BR, Budinger TF(1988) QuantitativeNMRmeasurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med 8, 200-208
3. Friedland RP, Budinger TF, Koss B, Ober AB (1985) Alzheimer's disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett 53, 235-240
4. Prior R, Monning U, Schreiter-Gasser U, Weidemann A, BlennowK, Gottfries CG, Masters CL, BeyreutherK(1991) Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett 124, 69-73
5. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245
6. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24, 87-97
7. Bürger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofman-Kiefer K, DeBernardis J, Kerkman D, McCulloch BS, Kohnken R, Padberg F, Pirttil ä T, Schapiro MB, Rapoport SI, Moeller H-J, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59, 1267-1272
8. Li SJ, Li Z, Wu G, Zhang MJ, Franczak M, Antuono PG (2002) Alzheimer Disease: Evaluation of a functional MR imaging index as a marker. Radiology 225, 253-259
9. Greicius MD, Srivastava G, Reiss AL, Menon V (2004) Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI. Proc Natl Acad Sci U S A 101, 4637-4642
10. Moseley M, Bammer R, Illes J (2002) Diffusion-Tensor imaging of cognitive performance. Brain Cogn 50, 396-413
11. Fellgiebel A,Wille P, Muller MJ,Winterer G, Scheurich A, Vucurevic G, Schmidt LG, Stoeter P (2004) Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: A diffusion tensor imaging study. Dement Geriatr Cogn Disord 18, 101-108
12. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, Schoenberg SO(2007) White matter damage in Alzheimer's disease and in mild cognitive impairment: Assessment with diffusion tensor MRI using parallel imaging techniques. Radiology 243, 483-492
13. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P (2005) Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study. Hum Brain Mapp 26, 231-239
14. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath M, Barletta J, Price JC, Sandell J, Lopresti BJ,Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319
15. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O (2011) Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls:Amulticentre phase 2 diagnostic study. Lancet Neurol 10, 424-435
16. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, De Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127
17. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128
18. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259
19. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319
20. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM (2011) Use of florbetapir-PET for imaging beta-Amyloid pathology. JAMA 305, 275-283
21. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68, 319-329
22. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465
23. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452
24. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66, 1469-1475
25. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27, 6174-6184
26. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494
27. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856-2866
28. Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC (2011) Cognition and beta-Amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 49, 2384-2390
29. Pike KE, Savage G,Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-Amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844
30. Sabri O, Kendziorra K, Wolf H, Gertz HJ, Brust P (2008) Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 35(Suppl 1), S30-S45
31. Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, Luthardt J, Schildan A, Patt M, Sorger D, Seese A, Gertz HJ, Sabri O (2011) Decreased cerebral alpha4beta2. nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 38, 515-525
32. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez De Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11CPiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372
33. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, HoltzmanDM(2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519
34. Weigand SD,Vemuri P,Wiste HJ, Senjem ML, Pankratz VS, Aisen PS,WeinerMW, Petersen RC, ShawLM,Trojanowski JQ, Knopman DS, Jack CR Jr (2011) Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 7, 133-141
35. Koivunen J, Pirttila T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hanninen T, Hallikainen M, Nagren K, Rinne JO, Soininen H (2008) PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-Amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 26, 378-383.
36. Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, DeKosky ST, Price JC (2006) Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 33, 94-102
37. Cohen AD, Price JC,Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, KlunkWE(2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: An example of brain reserve. J Neurosci 29, 14770-14778
38. Devanand DP, Mikhno A, Pelton GH, Cuasay K, Pradhaban G, Dileep Kumar JS, Upton N, Lai R, Gunn RN, Libri V, Liu X, van Heertum R, Mann JJ, Parsey RV (2010) Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG)PETin patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 23, 185-198
39. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 68, 501-508
40. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C,Yeatman T, Fox NC, Rossor MN (2006) Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C-PIB positron emission tomography study. Ann Neurol 60, 145-147
41. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O (2010) Beta-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74, 121-127
42. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 69, 1032-1042
43. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN (2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50, 1464-1470
44. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, HoltzmanDM(2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519
45. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144
46. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574
47. Buchhave P, Minthon L, Zetterberg H,Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
48. Trojanowski JQ, Hampel H (2011) Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol 95, 491-495
49. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, SternY,Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746
50. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, FaganAM,IwatsuboT, JackCRJr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic Guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
51. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269
52. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, PhelpsCH(2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279
53. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613
54. Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: Normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol 67, 688-696
55. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid betaprotein on hippocampal synaptic plasticity: A potent role for trimers. J Physiology 572, 477-492
56. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: Prevention by systemic passive immunization. J Neurosci 28, 4231-4237
57. Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, Trischmann L, Schaupp M, Penz M, Tiller FW, Bohm G (2007) Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J Alzheimers Dis 11, 117-125
58. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 29, 171-176
59. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M (2010) Highmolecular-weight beta-Amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24, 2716-2726
60. Ewers M, Zhong Z, Burger K,Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H (2008) Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 131, 1252-1258
61. Zhong Z, Ewers M, Teipel S, Burger K,Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64, 718-726
62. Ewers M, Cheng X, Zhong Z, Nural HF, Walsh C, Meindl T, Teipel SJ, Buerger K, He P, Shen Y, Hampel H (2011) Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. J Alzheimers Dis 25, 373-381
63. Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K (2010) Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 63, 326-330
64. Herrup K (2010) Reimagining Alzheimer's disease-An agebased hypothesis. J Neurosci 30, 16755-16762
65. Schneider P, Hampel H, BuergerK(2009) Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 15, 358-374
66. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144
67. Schneider P, Buerger K, Teipel S, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Rujescu D, Moeller HJ, ZetterbergH, BlennowK, Ernst A, Bergmann A, HampelH(2011) Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry 70, 145-151
68. Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, Patel PP, Ferrell E, Fournier DR, Kan CW, Campbell TG, Meyer R, Rivnak AJ, Pink BA, Minnehan KA, Piech T, Rissin DM, Duffy DC, Rubertsson S, Wilson DH, Blennow K (2011) Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PLoS One 6, e28263
69. Friston KJ (1994) Functional and effective connectivity in neuroimaging: A synthesis. Hum Brain Mapp 2, 56-78
70. Horwitz B (2003) The elusive concept of brain connectivity. Neuroimage 19, 466-470
71. Stephan KE, Friston KJ (2010) Analyzing effective connectivity with fMRI.Wiley Interdiscip Rev Cogn Sci 1, 446-459
72. Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O (2008) Mapping the structural core of human cerebral cortex. PLoS Biol 6, e159
73. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001) A default mode of brain function. Proc Natl Acad Sci U S A 98, 676-682
74. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P (2005) Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study. Hum Brain Mapp 26, 231-239
75. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA (2006) Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: An independent component analysis. J Neurosci 26, 10222-10231
76. Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL (2003) Functional deactivations: Change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 100, 14504-14509
77. Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF (2006) Consistent restingstate networks across healthy subjects. Proc Natl Acad Sci U S A 103, 13848-13853
78. Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, Wu T, Jiang T, Li K (2006) Changes in hippocampal connectivity in the early stages of Alzheimer's disease: Evidence from resting state fMRI. Neuroimage 31, 496-504
79. Supekar K, Menon V, Rubin D, Musen M, Greicius MD (2008) Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol 4, e1000100
80. Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, Kramer JH, Weiner M, Miller BL, Seeley WW (2010) Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 133, 1352-1367
81. Biswal B, Yetkin FZ, Haughton VM, Hyde JS (1995) Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med 34, 537-541
82. Calhoun VD, Adali T (2006) Unmixing fMRI with independent component analysis. IEEE Eng Med Biol Mag 25, 79-90
83. Calhoun VD, Kiehl KA, Pearlson GD (2008) Modulation of temporally coherent brain networks estimated using ICA at rest and during cognitive tasks. Hum Brain Mapp 29, 828-838
84. Beckmann CF, DeLuca M, Devlin JT, Smith SM (2005) Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 360, 1001-1013
85. Qi Z, Wu X, Wang Z, Zhang N, Dong H, Yao L, Li K (2010) Impairment and compensation coexist in amnestic MCI default mode network. Neuroimage 50, 48-55
86. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, Drzezga A, Forstl H, Kurz A, Zimmer C, Wohlschlager AM (2007) Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A 104, 18760-18765
87. Gili T, Cercignani M, Serra L, Perri R, Giove F, Maraviglia B, Caltagirone C, Bozzali M (2011) Regional brain atrophy and functional disconnection across Alzheimer's disease evolution. J Neurol Neurosurg Psychiatry 82, 58-66
88. Wang K, Liang M,Wang L, Tian L, Zhang X, Li K, Jiang T (2007) Altered functional connectivity in early Alzheimer's disease: A resting-state fMRI study. Hum Brain Mapp 28, 967-978
89. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178-188
90. Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA (2011) Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134, 1635-1646
91. Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8, 448-460
92. Bosch B, Bartres-Faz D, Rami L, Arenaza-Urquijo EM, Fernandez-Espejo D, Junque C, Sole-Padulles C, Sanchez-Valle R, Bargallo N, Falcon C, Molinuevo JL (2010) Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnestic mild cognitive impairment and mild Alzheimer's disease. Cortex 46, 451-461
93. Koch W, Teipel S, Mueller S, Benninghoff J, Wagner M, Bokde AL, Hampel H, Coates U, Reiser M, Meindl T (2012) Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiol Aging 33, 466-478
94. Fleisher AS, Sherzai A, Taylor C, Langbaum JB, Chen K, Buxton RB (2009) Resting-state BOLD networks versus task-Associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage 47, 1678-1690
95. Meindl T, Teipel S, Elmouden R, Mueller S, KochW, Dietrich O, Coates U, Reiser M, Glaser C (2010) Test-retest reproducibility of the default-mode network in healthy individuals. Hum Brain Mapp 31, 237-246
96. Zuo XN, Kelly C, Adelstein JS, Klein DF, Castellanos FX, Milham MP (2010) Reliable intrinsic connectivity networks: Test-retest evaluation using ICA and dual regression approach. Neuroimage 49, 2163-2177
97. Shehzad Z,Kelly AM, Reiss PT, Gee DG, Gotimer K, Uddin LQ, Lee SH, Margulies DS, Roy AK, Biswal BB, Petkova E, Castellanos FX, Milham MP (2009) The resting brain: Unconstrained yet reliable. Cereb Cortex 19, 2209-2229
98. Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, Beckmann CF, Adelstein JS, Buckner RL, Colcombe S, Dogonowski AM, Ernst M, Fair D, Hampson M, Hoptman MJ, Hyde JS, Kiviniemi VJ, Kotter R, Li SJ, Lin CP, Lowe MJ, Mackay C, Madden DJ, Madsen KH, Margulies DS, Mayberg HS, McMahon K, Monk CS, Mostofsky SH, Nagel BJ, Pekar JJ, Peltier SJ, Petersen SE, Riedl V, Rombouts SA, Rypma B, Schlaggar BL, Schmidt S, Seidler RD, Siegle GJ, Sorg C, Teng GJ, Veijola J, Villringer A, Walter M, Wang L, Weng XC, Whitfield-Gabrieli S, Williamson P, Windischberger C, Zang YF, Zhang HY, Castellanos FX, Milham MP (2010) Toward discovery science of human brain function. Proc Natl Acad Sci U S A 107, 4734-4739
99. Neil JJ (2008) Diffusion imaging concepts for clinicians. J Magn Reson Imaging 27, 1-7
100. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, Comi G, Filippi M (2002) White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry 72, 742-746
101. Bozzali M, Franceschi M, Falini A, Pontesilli S, Cercignani M, Magnani G, Scotti G, Comi G, Filippi M (2001) Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. Neurology 57, 1135-1137
102. Choi SJ, Lim KO, Monteiro I, Reisberg B (2005) Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: A preliminary study. J Geriatr Psychiatry Neurol 18, 12-19
103. Fellgiebel A, Muller MJ,Wille P, Dellani PR, Scheurich A, Schmidt LG, Stoeter P (2005) Color-coded diffusion-Tensorimaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging 26, 1193-1198
104. Huang J, AuchusAP(2007) Diffusion tensor imaging of normal appearing white matter and its correlation with cognitive functioning in mild cognitive impairment and Alzheimer's disease. Ann N Y Acad Sci 1097, 259-264
105. Medina D, Detoledo-Morrell L, Urresta F, Gabrieli JD, MoseleyM, Fleischman D, Bennett DA, Leurgans S, Turner DA, Stebbins GT (2006) White matter changes in mild cognitive impairment and AD:Adiffusion tensor imaging study. Neurobiol Aging 27, 663-672
106. Naggara O, Oppenheim C, Rieu D, Raoux N, Rodrigo S, Dalla Barba G, Meder JF (2006) Diffusion tensor imaging in early Alzheimer's disease. Psychiatry Res 146, 243-249
107. Xie D, Chen L, Liu C, Liu K (2006) The inhibitory effects of oxytocin on distal colonic contractile activity in rabbits are enhanced by ovarian steroids. Acta Physiol (Oxf) 186, 141-149
108. Zhang Y, Schuff N, Jahng GH, Bayne W, Mori S, Schad L, Mueller S, Du AT, Kramer JH, Yaffe K, Chui H, Jagust WJ, Miller BL,Weiner MW (2007) Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 68, 13-19
109. Friese U, Meindl T, Herpertz SC, Reiser MF, Hampel H, Teipel SJ (2010) Diagnostic utility of novel MRI-based biomarkers for Alzheimer's disease: Diffusion tensor imaging and deformation-based morphometry. J Alzheimers Dis 20, 477-490
110. Muller MJ, Greverus D,Weibrich C, Dellani PR, Scheurich A, Stoeter P, Fellgiebel A (2007) Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol Aging 28, 398-403
111. Taoka T, Iwasaki S, Sakamoto M, Nakagawa H, Fukusumi A, Myochin K, Hirohashi S, Hoshida T, KichikawaK(2006) Diffusion anisotropy and diffusivity of white matter tracts within the temporal stem in Alzheimer disease: Evaluation of the 'tract of interest' by diffusion tensor tractography. AJNR Am J Neuroradiol 27, 1040-1045
112. Yasmin H, Nakata Y, Aoki S, Abe O, Sato N, Nemoto K, Arima K, Furuta N, Uno M, Hirai S, Masutani Y, Ohtomo K (2008) Diffusion abnormalities of the uncinate fasciculus in Alzheimer's disease: Diffusion tensor tract-specific analysis using a new method to measure the core of the tract. Neuroradiology 50, 293-299
113. Teipel SJ, Stahl R, Dietrich O, Schoenberg SO, Perneczky R, Bokde AL, Reiser MF, Moller HJ, Hampel H (2007) Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage 34, 985-995
114. Grana M, Termenon M, Savio A, Gonzalez-Pinto A, Echeveste J, Perez JM, Besga A (2011) Computer Aided Diagnosis system for Alzheimer Disease using brain Diffusion Tensor Imaging features selected by Pearson's correlation. Neurosci Lett 502, 225-229
115. Cui Y, Wen W, Lipnicki DM, Beg MF, Jin JS, Luo S, Zhu W, Kochan NA, Reppermund S, Zhuang L, Raamana PR, Liu T, Trollor JN, Wang L, Brodaty H, Sachdev PS (2011) Automated detection of amnestic mild cognitive impairment in community-dwelling elderly adults: A combined spatial atrophy and white matter alteration approach. Neuroimage 59, 1209-1217
116. Acosta-Cabronero J, Williams GB, Pengas G, Nestor PJ (2010) Absolute diffusivities define the landscape of white matter degeneration in Alzheimer's disease. Brain 133, 529-539
117. O'Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O'Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, HampelH(2011) Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. PLoS One 6, e21745
118. Del Ser T, Hachinski V, Merskey H, Munoz DG (1999) An autopsy-verified study of the effect of education on degenerative dementia. Brain 122(Pt 12), 2309-2319
119. McDowell I (2001) Alzheimer's disease: Insights from epidemiology. Aging (Milano) 13, 143-162
120. Brayne C, Ince PG, Keage HA, McKeith IG, Matthews FE, Polvikoski T, Sulkava R (2010) Education, the brain and dementia: Neuroprotection or compensation? Brain 133, 2210-2216
121. Perneczky R, Drzezga A, Diehl-Schmid J, Schmid G, Wohlschlager A, Kars S, Grimmer T, Wagenpfeil S, Monsch A, Kurz A (2006) Schooling mediates brain reserve in Alzheimer's disease: Findings of fluoro-deoxyglucose-positron emission tomography. J Neurol Neurosurg Psychiatry 77, 1060-1063
122. PerneczkyR,Wagenpfeil S, Lunetta KL, Cupples LA, Green RC, DeCarli C, Farrer LA, Kurz A (2009) Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: The MIRAGE study. J Alzheimers Dis 17, 855-862
123. PerneczkyR,Wagenpfeil S, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA, Kurz A (2010) Head circumference, atrophy, and cognition: Implications for brain reserve in Alzheimer disease. Neurology 75, 137-142
124. Teipel SJ, Meindl T, Wagner M, Kohl T, Burger K, Reiser MF, Herpertz S, Moller HJ, Hampel H (2009) White matter microstructure in relation to education in aging and Alzheimer's disease. J Alzheimers Dis 17, 571-583
125. Teipel SJ, Reuter S, Stieltjes B, Acosta-Cabronero J, Ernemann U, Fellgiebel A, Filippi M, Frisoni G, Hentschel F, Jessen F, Klöppel S, Meindl T, Pouwels PJW, Hauenstein K, Hampel H (2011) Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Res Neuroimage 194, 363-371
126. Damoiseaux JS, Greicius MD (2009) Greater than the sum of its parts:Areviewof studies combining structural connectivity and resting-state functional connectivity. Brain Struct Funct 213, 525-533
127. Honey CJ, Sporns O, Cammoun L, Gigandet X, Thiran JP, Meuli R, Hagmann P (2009) Predicting human resting-state functional connectivity from structural connectivity. Proc Natl Acad Sci U S A 106, 2035-2040
128. Greicius MD, Supekar K, Menon V, Dougherty RF (2009) Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex 19, 72-78
129. van den Heuvel M, Mandl R, Luigjes J, Hulshoff Pol H (2008) Microstructural organization of the cingulum tract and the level of default mode functional connectivity. J Neurosci 28, 10844-10851
130. Teipel SJ, Bokde AL, Meindl T, Amaro E Jr, Soldner J, ReiserMF, Herpertz SC, Moller HJ, HampelH(2010) White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage 49, 2021-2032
131. Plant C, Teipel SJ, Oswald A, Bohm C, Meindl T, Mourao-Miranda J, Bokde AW, Hampel H, Ewers M (2010) Automated detection of brain atrophy patterns based onMRI for the prediction of Alzheimer's disease. Neuroimage 50, 162-174
132. Mourao-Miranda J, Bokde AL, Born C, Hampel H, Stetter M (2005) Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage 28, 980-995
133. Oishi K, Akhter K, Mielke M, Ceritoglu C, Zhang J, Jiang H, Li X, Younes L, Miller MI, van Zijl PC, Albert M, Lyketsos CG, Mori S (2011) Multi-modal MRI analysis with disease-specific spatial filtering: Initial testing to predict mild cognitive impairment patients who convert to Alzheimer's disease. Front Neurol 2, 54
134. Ewers M, Sperling RA, Klunk WE,WeinerMW, Hampel H (2011) Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 34, 430-442
135. Ewers M, Teipel SJ, Dietrich O, Schonberg SO, Jessen F, Heun R, Scheltens P, van De Pol L, Freymann NR, Moeller HJ, Hampel H (2006) Multicenter assessment of reliability of cranial MRI. Neurobiol Aging 27, 1051-1059
136. Kruggel F, Turner J, Muftuler LT (2010) Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. Neuroimage 49, 2123-2133
137. Jovicich J, Czanner S, Han X, Salat D, van der Kouwe A, Quinn B, Pacheco J, Albert M, Killiany R, Blacker D, Maguire P, Rosas D, Makris N, Gollub R, Dale A, Dickerson BC, Fischl B (2009) MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 46, 177-192
138. Teipel SJ, Ewers M, Wolf S, Jessen F, Kolsch H, Arlt S, Luckhaus C, Schonknecht P, SchmidtkeK, Heuser I, Frolich L, Ende G, Pantel J,Wiltfang J, Rakebrandt F, Peters O, Born C, Kornhuber J, Hampel H (2010) Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Res 182, 244-250
139. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, Whitwell JL, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, GloverG, Mugler J,WeinerMW(2008) The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27, 685-691
140. Leow AD, Klunder AD, Jack CR Jr, Toga AW, Dale AM, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Whitwell JL, Borowski BJ, Fleisher AS, Fox NC, Harvey D, Kornak J, Schuff N, Studholme C, Alexander GE,WeinerMW, Thompson PM (2006) Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 31, 627-640
141. Suckling J, Barnes A, Job D, Brenan D, Lymer K, Dazzan P, Marques TR, MacKay C, McKie S, Williams SR, Williams SC, Lawrie S, Deakin B (2010) Power calculations for multicenter imaging studies controlled by the false discovery rate. Hum Brain Mapp 31, 1183-1195
142. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW, the As, Disease Neuroimaging I (2009)MRIof hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132, 1067-1077
143. Stonnington CM, Tan G, Kloppel S, Chu C, Draganski B, Jack CR Jr, Chen K, Ashburner J, Frackowiak RS (2008) Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease. Neuroimage 39, 1180-1185
144. Clarkson MJ, Ourselin S, Nielsen C, Leung KK, Barnes J, Whitwell JL, Gunter JL, Hill DL, Weiner MW, Jack CR Jr, Fox NC (2009) Comparison of phantom and registration scaling corrections using the ADNI cohort. Neuroimage 47, 1506-1513
145. Teipel SJ, Peters O, Heuser I, Jessen F, MaierW, Froelich L, Arlt S, Hull M, Gertz HJ, Kornhuber J,Wiltfang J, Thome J, RienhoffO,Meindl T, Hampel H, GrotheM(2011) Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. World J Biol Psychiatry 12(Suppl 1), 109-113
146. Marenco S, Rawlings R, Rohde GK, Barnett AS, Honea RA, Pierpaoli C,Weinberger DR (2006) Regional distribution of measurement error in diffusion tensor imaging. Psychiatry Res 147, 69-78
147. Vollmar C, O'Muircheartaigh J, Barker GJ, Symms MR, Thompson P, Kumari V, Duncan JS, Richardson MP, Koepp MJ (2011) Identical, but not the same: Intra-site and intersite reproducibility of fractional anisotropy measures on two 3.0T scanners. Neuroimage 51, 1384-1394
148. Cercignani M, Bammer R, Sormani MP, Fazekas F, Filippi M (2003) Inter-sequence and inter-imaging unit variability of diffusion tensor MR imaging histogram-derived metrics of the brain in healthy volunteers. AJNR Am J Neuroradiol 24, 638-643
149. Pfefferbaum A, Adalsteinsson E, Sullivan EV (2003) Replicability of diffusion tensor imaging measurements of fractional anisotropy and trace in brain. JMagn Reson Imaging 18, 427-433
150. Teipel SJ, Reuter S, Stieltjes B, Acosta-Cabronero J, Ernemann U, Fellgiebel A, Filippi M, Frisoni G, Hentschel F, Jessen F, Kloppel S, Meindl T, Pouwels PJ, Hauenstein KH, Hampel H (2011) Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Res 194, 363-371
151. Wang JY, Abdi H, Bakhadirov K, Diaz-Arrastia R, Devous MD Sr (2012) A comprehensive reliability assessment of quantitative diffusion tensor tractography. Neuroimage 60, 1127-1138
152. Zhu T, Hu R, Qiu X, Taylor M, Tso Y, Yiannoutsos C, Navia B, Mori S, Ekholm S, Schifitto G, Zhong J (2011) Quantification of accuracy and precision of multi-center DTI measurements:Adiffusion phantom and human brain study. Neuroimage 56, 1398-1411
153. Zhu T, Liu X, Gaugh MD, Connelly PR, Ni H, Ekholm S, Schifitto G, Zhong J (2009) Evaluation of measurement uncertainties in human diffusion tensor imaging (DTI)-derived parameters and optimization of clinical DTI protocols with a wild bootstrap analysis. J Magn Reson Imaging 29, 422-435
154. Zhu T, Liu X, Connelly PR, Zhong J (2008) An optimized wild bootstrap method for evaluation of measurement uncertainties of DTI-derived parameters in human brain. Neuroimage 40, 1144-1156
155. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574
156. Stoppe G, Haak S, Knoblauch A, Maeck L (2007) Diagnosis of dementia in primary care:Arepresentative survey of family physicians and neuropsychiatrists in Germany. Dement Geriatr Cogn Disord 23, 207-214